Eliem Therapeutics announced it has received an investment‑bank analyst rating update, as reported by Pro News on 8 April 2026.
The release was first published at 03:29 am and subsequently updated at 03:35 am the same day, with no further details.
No specific rating level, upgrade, downgrade, or target‑price change was disclosed, limiting immediate market implications.